Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking

Philippe Maury1
Anne Rollin1
Michel Galinier1
Yves Juillière2
1University Hospital Rangueil, Toulouse, France; 2Institut Lorrain du Coeur des Vaisseaux Louis Mathieu, Nancy, France

Abstract: Although digitalis has been used since the last century, it seems to be in the process of being progressively abandoned. However, digoxin has demonstrated a large positive benefit in terms of reduction of morbidity in heart failure patients with sinus rhythm, while the sometimes-observed increase in mortality is dramatically reduced with low serum concentrations. Digoxin, which is the only digitalis currently available, remains one of three drugs used for rate control in atrial fibrillation. Even if digoxin alone is insufficient to provide rate control during exertion in most patients, the optimal cardiac rate both at rest and at exertion is still undetermined, as is the importance of achieving sufficient rate control in asymptomatic patients. Because of its low cost and the accumulated knowledge and expertise about prescription, digoxin probably will remain an undisputed medication for rate control for atrial fibrillation, especially for heart failure patients.

Keywords: digitalis, heart failure, atrial fibrillation, heart rate

Introduction

Digitalis’ first use can be traced back to 2 centuries ago, in 1785, when William Withering described the properties of the leaves of the common foxglove plant Digitalis purpurea.1 However, after an enormous amount of use in treating heart failure, digoxin, which seems to be the last digitalis product available on the world market for medical purpose, is on the way to being filed under “endangered drugs” because of the discovery of other powerful agents for treating heart failure patients. Digoxin is, however, still widely used for controlling the heart rate during AF. In this article, we present an overview of the current and future roles of digoxin in AF.

Cellular, neurohormonal, and electrophysiological properties of digoxin

Many cardiovascular effects of digoxin have been reported, and most, if not all, are directly or indirectly related to the inhibition of sodium-potassium adenosine triphosphatase (Na-K ATPase) activity.

The inotropic properties of digoxin are the foundation for the role of this medication in heart failure. These properties seem mainly to be a result of the inhibition of Na-K ATPase activity of the myocardial cells, leading to cellular sodium overload and then to an increase in sarcoplasmic calcium content mediated by the Na/Ca exchanger. Such a higher calcium loading is clearly related to a higher calcium induced-calcium release and to stronger myocardial contractility.2 Activation of the Na/Ca exchanger itself is, however, not powerful enough to achieve therapeutic or toxic intracellular lev-
Maury et al

Inhibition of Na-K ATPase

Higher calcium cellular loading  
Increased sensitivity of baroreceptors  
Increase in parasympathetic activity

Sensitization of the sympathetic and vagal afferent pathways

Stimulating central effect on the sympathetic and parasympathetic tone

Diuretic action

Arterial and venous vasoconstriction

**Figure 1**  Mechanisms of action of digoxin.

**Abbreviation:** Na-K ATPase, sodium-potassium adenosine triphosphatase.
atrioventricular node, leading to an increase in refractory periods and nodal conduction time.\textsuperscript{15,16} During AF, the ventricular rate is mainly dependent on the properties of the atrioventricular node, which are influenced by drugs, the neurovegetative tone, and the rate and regularity of atrial depolarizations. Therefore, digoxin decreases the cardiac rate during AF, especially in cases of heart failure, because of its negative dromotropic effect on the atrioventricular node and because of an increase in the atrial rate, leading to more concealed conduction into the atrioventricular node.\textsuperscript{18} However, this action is only significant at rest and is far less present at exertion, when the sympathetic tone is dominant. In patients with AF and heart failure, the decrease in cardiac rate may increase cardiac output, which in turn may further decrease sympathetic tone. Electrophysiological actions of digoxin at different levels are depicted in Table 1.

**Digoxin and heart failure in sinus rhythm**

The use of digoxin in patients with congestive heart failure and with sinus rhythm has been a matter of debate, even it had been long recognized that some heart failure patients did improve clinically with digoxin treatment. From 1993 to 1997, the Prospective Randomized study Of Ventricular failure and the Efficacy of Digoxin (PROVED), Randomized Assessment of Digoxin on Inhibitors of Angiotensin-Converting Enzyme (RADIANCE), and Digitalis Investigation Group (DIG) trials demonstrated clinical and left ventricular function improvements with digoxin in mild to moderate heart failure in patients in the sinus rhythm, without any detrimental or positive effect on survival, especially in patients with mild heart failure.\textsuperscript{17-20} In patients with severe heart failure and sinus rhythm, digoxin also demonstrated a significant reduction in the risk of the 2-year composite endpoint of heart failure mortality and hospitalizations.\textsuperscript{21} In a subset of the DIG trial, digoxin was associated with long-term improvement in kidney function in 15% of patients, leading to a reduction in death or hospitalization.\textsuperscript{22} One should acknowledge, however, that currently considered optimal therapy (angiotensin-converting-enzyme inhibitors and beta-blockers) was not available or was poorly prescribed at this time.

However, on DIG post hoc analysis, digoxin therapy was associated with an increased risk of death from any cause among women (but not men),\textsuperscript{23} but a decreased mortality for concentrations lower than 1 ng/mL.\textsuperscript{24} Mortality and morbidity also have been shown to be increased after the use of digoxin when prescribed in the elderly.\textsuperscript{25} More recent comparative data prove, in fact, that the effects of digoxin on morbidity and mortality are similar to those of ivabradin\textsuperscript{26} because of the pivotal role of a low cardiac rate in patients with heart failure. Finally, some recent works argue against any detrimental role of digoxin in heart failure and even demonstrate a favorable profile of the drug on mortality\textsuperscript{27,28} (but AF was present in some of the studied patients), whereas digoxin use was associated with a higher mortality in other works.\textsuperscript{29,30} However, in one of these studies,\textsuperscript{31} mean serum digoxin concentration was 1.02 ng/mL, thereby suggesting too high a level was prescribed in many patients. In a very recent study of systolic heart failure patients, a discharge prescription of digoxin was associated with lower all-cause hospital readmission, without higher mortality, but only in those patients with an ejection fraction lower than 45%.\textsuperscript{31}

There have also been many controversies about the risk of digoxin in patients with ischemic heart disease. An early retrospective study already suggested that digoxin increased the early mortality of myocardial infarction patients with congestive heart failure and complex ventricular premature beats.\textsuperscript{32} However, digoxin was not an independent risk factor contributing significantly to mortality in patients with coronary artery disease according to the Coronary Artery Surgery Study (CASS) Registry.\textsuperscript{33} Compared with captopril, digoxin improves general well-being and symptoms, whereas worsening of angina is more frequent with captopril compared with digoxin in patients with ischemic heart disease.\textsuperscript{34} However, cardiovascular events are lower with captopril compared with digoxin.\textsuperscript{34} As a result of many other studies in that area, it has finally been accepted that digoxin is not harmful in coronary artery disease patients with heart failure.

As a result of all these data, current guidelines for heart failure\textsuperscript{35} do not recommend digoxin as a primary medication in patients in sinus rhythm, despite the lack of harmful
effect and the recognized positive actions on morbidity. No new trial has been planned since then, probably because of the lack of interest from the pharmacological industry in this old and generic drug, avoiding any oncoming change in the guidelines.

**Digoxin in patients with AF**

A completely different situation happens in the case of AF. Whether the patient presents with heart failure or not, AF may be still an indication for digoxin. It was recognized early on that discontinuation of digoxin may induce clinical worsening of congestive symptoms in heart failure patients with AF. However, it should be acknowledged that data on the use of digoxin in AF patients are limited because the main prospective randomized controlled trials with digoxin were performed in patients with heart failure and sinus rhythm, whereas such trials are still not available for patients with AF.

In the Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) III and V trials, AF patients taking digoxin were seen to have a higher mortality (4.22%/patient-year compared with 2.66%/patient-year), and this persisted after multivariate risk factor adjustment (hazard ratio [HR], 1.53). The increased mortality rate linked to digoxin was found to be even larger in patients with heart failure.37

The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial was dedicated to compare “rate” versus “rhythm” control in patients with paroxysmal or persistent AF.38 Digoxin was linked to a poorer survival in AFFIRM,39 but this was initially perceived as representing the prescription of digoxin for patients at greater risk of death, such as those with heart failure, rather than reflecting a deleterious effect of digoxin on survival. Recent post hoc analysis of this trial concluded there was no evidence of increased mortality or hospitalization in those taking digoxin as baseline initial therapy.40 However, data from the same population in another post hoc analysis revealed that digoxin was associated with an increase in all-cause mortality (HR, 1.41; \( p<0.001 \)) (whatever the sex), cardiovascular mortality (HR, 1.35; \( p=0.016 \)), and arrhythmic mortality (HR, 1.61; \( p=0.009 \)), and that all-cause mortality was increased with digoxin in patients without (HR, 1.37; \( p=0.019 \)) or with (HR, 1.41; \( p=0.01 \)) heart failure.41 Similar observations were made when restricted to patients randomized to the rate control-only cohort (HR, 1.46 [95% confidence interval, 1.13–1.90]; \( p=0.004 \)).

Such diverging results from the same population are difficult to explain. One explanation is that high serum levels were encouraged in the AFFIRM protocol (\( \geq 1.0 \) ng/mL), which has been shown to lead to an increased mortality.42 Moreover, many patients were excluded because of missing data; these are not prospective trials, and many important parameters such as cardiomyopathy, symptoms of AF, renal failure, degree of heart failure, and failure of antiarrhythmic drugs were different or not indicated for patients on and off digoxin. Finally, digoxin use was assessed at a fixed time of initial therapy at randomization in one study40 while being treated as a time-dependent covariate, accounting for changes in digoxin use over time, in the other one.41 Of note is that similar post hoc analysis for the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) Trial, in which around 65% of patients in both the rate and rhythm control groups were given digoxin, is not available.42 Other recent studies argue against any detrimental independent role of digoxin on mortality and hospitalizations in AF patients43 or even show that rehospitalization in heart failure patients with AF is decreased in those taking digoxin.31

A summary of the role of digoxin in patients with sinus rhythm versus AF is shown in Table 2.

**Clinical role of digoxin in AF**

Digoxin is used to control heart rate in 35%–70% of patients with AF.44 According to the AF guidelines, because of its properties on the atrioventricular node, digoxin is one of the main drugs used for controlling the ventricular rate in AF. The main goal is to maintain the cardiac rate into appropriate limits, both at rest and during exertion or stress. Excessive cardiac rates may lead to palpitations, dizziness, and discomfort or to dyspnea and congestive heart failure, even in cases of preserved left ventricular systolic function, mainly because of altered filling resulting from the decreased diastolic time and the loss of atrial contraction. When sustained for a long time, AF with inappropriately fast cardiac rates may lead to tachycardia-induced cardiomyopathy, a form of cardiomyopathy with reduced systolic function, characterized by its regression when the cardiac rate normalizes. AF-induced

<table>
<thead>
<tr>
<th>Sinus rhythm</th>
<th>Atrial fibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical and left ventricular function improvements</td>
<td>No prospective trial; increase in mortality or not, depending on the post hoc analysis</td>
</tr>
<tr>
<td>Reduction in heart failure mortality or hospitalizations</td>
<td>No increase in mortality for concentrations &lt;1 ng/mL</td>
</tr>
</tbody>
</table>

---

**Table 2** Digoxin in patients in sinus rhythm versus atrial fibrillation

---

Maury et al

*Research Reports in Clinical Cardiology 2014:5*
tachycardia-induced cardiomyopathy is very frequent, even in case of associated heart disease, because maintenance of sinus rhythm in heart failure patients with AF may significantly increase the left ventricular ejection fraction, not only in patients without concurrent structural heart disease (+24%) and those with inadequate rate control before ablation (+23%) but also in those with coexisting heart disease (+16%) and adequate rate control before ablation (+17%). These changes are even substantially greater in patients with baseline more severe impairment of LV function. Deterioration of LV function appears to be related to both the cardiac rate and the duration of AF. In addition, in patients with lone AF, the rate control by ablation of the atrioventricular conduction may lead to an increase in LV ejection fraction and a decrease in LV-end-systolic and end-diastolic dimensions.

If the clinical benefits of lowering heart rate by digoxin, especially for heart failure patients with AF, have already been proved, it is somewhat paradoxical to see that mortality seems to be increased in AF patients taking digoxin, at least in some works (see earlier text). Although a definitive answer to this dilemma will need additional prospective trials, one can, however, conclude that if harmful effects of digoxin in AF patients exist, they are probably of lower clinical relevance compared with the drug’s clinical benefit, provided that doses are adapted and that clinical and biological monitoring is continued.

What is the optimal cardiac rate during AF? This issue does not seem to have been definitively assessed. The optimal level of heart rate control with respect to morbidity, mortality, quality of life, and symptoms remains unknown. The lower cardiac output resulting from loss of atrial contraction during AF should be corrected by an accelerated heart rate, which should not exceed certain limits. But what are these limits, both at rest and at exertion? Cardiac output was always found to be proportional to the heart rate when the ventricular rate was less than 90 beats per minute but was inversely proportional in around half the patients with a ventricular rate greater than 90 beats per minute, and always decreased for heart rates higher than 140 beats per minute. Because atrial contraction is thought to be responsible for 20%–50% of the stroke volume in sinus rhythm, the ventricular rate needs to be 20%–50% higher than in sinus rhythm to maintain normal cardiac output. In patients with AF (most receiving digoxin), the maximal heart rate during maximal exercise test exceeds the age-adjusted maximal heart rate by a mean of 20 beats per minute (50 beats per minute), although patients with lone AF demonstrated normal exercise capacity. This highlights the relative lack of clinical relevance of maximal heart rates during AF, at least for healthy hearts.

In the American College of Cardiology/American Heart Association/European Society of Cardiology Guidelines for the Management of Patients with Atrial Fibrillation from 2006, the criteria for rate control was to achieve ventricular rates between 60 and 80 beats per minute at rest and between 90 and 115 beats per minute during moderate exercise. This was mainly based on the results of the AFFIRM trial, in which adequate control was defined as an average heart rate up to 80 beats per minute at rest, and either an average rate up to 100 beats per minute over ambulatory Holter monitoring, with no rate above 100% of the maximum age-adjusted predicted exercise heart rate, or a maximum heart rate of 110 beats per minute during a 6-minute walk test. Higher resting heart rates were, however, not associated with an adverse prognosis. In the Rate Control versus Electrical Cardioversion (RACE) trial, rate control was defined as less than 100 beats per minute at rest. In the AF-CHF trial, rate control was to achieve a target heart rate of 80 beats per minute at rest or 110 beats per minute during a 6-minute walk test.

However, more recent AF guidelines somewhat changed this perception. The RACE II trial did not identify a benefit of “stringent” rate control (resting heart rate, 80 beats per minute, and an adequate increase in heart rate on moderate exertion) over “lenient” rate control (resting heart rate of 110 beats per minute). Symptoms, adverse events, and quality of life were similar in both groups. A “lenient” rate control therapy approach was therefore considered reasonable in patients without severe symptoms because of a high ventricular rate. On this basis, both the 2010 European guidelines for the management of AF and the 2011 American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society focused update suggest that an initially lenient rate control approach should be used, with dosing of rate control drugs being increased and drugs being combined until this target has been achieved. If patients remain symptomatic, or in patients with altered ejection fraction, a stricter rate control target should be pursued (resting heart rate, 80 and 110 beats per minute during moderate exercise or during a 6-minute walk).

The role of digoxin in AF
Rate control is achieved using pharmacological interventions in most of the patients with AF, with only a minority requiring implantation of a pacemaker for symptomatic bradycardia or atrioventricular node ablation/modification. Digoxin, beta-blockers, and nondihydropyridine calcium channel antagonists are essentially used for that purpose. Because the
main mechanism for dromotropic action of digoxin during AF relies on an increased vagal tone (see earlier text), the ability of digoxin to decrease heart rate during adrenergic drives is limited or even absent; thus, digoxin is effective for control of heart rate at rest, but not during exercise, although 70% of AFFIRM patients receiving digoxin alone were found to have rate control at exercise.\(^3\) Importantly, a satisfying resting heart rate under digoxin does absolutely not imply an adequate rate at exertion. Thus, beta-blockers or calcium channel antagonists are the preferred drugs, especially for patients without significantly depressed left ventricular systolic function, whereas the combination of a beta-blocker and digoxin may be beneficial in patients with heart failure. In the patients randomized to rate control in the AFFIRM trial, adequate rate control was achieved in 58% of patients with the first drug or combination (70% with beta-blockers \pm digoxin, 54% with calcium channel blockers \pm digoxin, and 58% with digoxin alone).\(^4\) Overall, digoxin was prescribed in 63% of patients (either as a sole drug or in combination) for adequate rate control.\(^5\) Rate control was achieved with digoxin alone in 54% of heart failure patients and in 71% of the other patients.\(^6\) In the AF-CHF trial, adequate rate control was achieved in 82%--88% of patients during the follow-up, using adjusted doses of beta-blockers with digoxin.\(^7\) Of note is that because no superiority of rhythm control over rate control was observed in this trial, it is tempting to conclude that the rate control was probably optimal with beta-blockers and digoxin in this population.

### Antiarrhythmic role of digoxin in AF

Digoxin is devoid of any antiarrhythmic property and may even promote and lengthen the duration of paroxysmal episodes of AF because of the increase of vagal tone and the reduction of atrial refractory periods.\(^57,58\)

### Potential hazards for prescribing digoxin in AF patients

Digoxin has a narrow therapeutic margin and may induce potentially severe adverse effects.\(^59,60\) Bradycardia and gastrointestinal or neurological disorders are the early warning signs for digoxin toxicity, which could be detected by simple clinical monitoring; dosing is not always sufficient. Special care is required for patients with renal failure, elderly patients, and patients receiving potentially interacting drugs (see Table 3).\(^59,60\) As digoxin levels are mainly dependent on renal elimination, very special attention has to be given when it is prescribed to patients with altered renal functions, and reduced doses and careful clinical and biological monitoring are required.

Some extracardiac risks have been described when using digoxin, which should be known even if there is the probability of marginal relevance. Experimentally, increased intracellular calcium is a key event in platelet activation and endothelial cell function, and digoxin activates platelets in vitro, whereas endogenous digoxin-like substances affect biologic processes in endothelial cells. In fact, non-valvular AF patients taking digoxin have increased levels of P-selectin (CD62P) expression in platelets and increased markers of endothelial activation, even if no greater risk for thromboembolism has been described using digoxin so far. Digoxin treatment has been linked with an increased incidence of breast cancer.\(^62\) Mortality is increased in hemodialysis patients taking digoxin, especially for high dosing and low potassium levels.\(^63\)

#### Table 3 Digoxin and drug or ionic disturbance interactions

<table>
<thead>
<tr>
<th>Drug and ionic disturbances</th>
<th>Mechanism of interaction</th>
<th>Adverse effects</th>
<th>How to prevent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verapamil</td>
<td>Increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Reduce digoxin dosing</td>
</tr>
<tr>
<td>Amiodarone (high dosing only)</td>
<td>Increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Reduce digoxin dosing</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>Increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Reduce digoxin dosing</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Reduce digoxin dosing</td>
</tr>
<tr>
<td>Propafenone</td>
<td>Increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Reduce digoxin dosing</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>Increases digoxin toxicity (increases Na-K ATPase fixation of digoxin); increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Control K level</td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>Increases digoxin toxicity</td>
<td>Digoxin toxicity</td>
<td>Avoid Ca perfusion</td>
</tr>
<tr>
<td>Diuretics</td>
<td>Hypokalemia</td>
<td>See hypokalemia</td>
<td>Control K level</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Reduce digoxin dosing</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Reduce digoxin dosing</td>
</tr>
<tr>
<td>Macrolides</td>
<td>Increases serum digoxin concentration</td>
<td>Digoxin toxicity</td>
<td>Reduce digoxin dosing</td>
</tr>
</tbody>
</table>

**Abbreviation:** Na-K ATPase, sodium-potassium adenosine triphosphatase.
The future of digoxin

In terms of heart failure with sinus rhythm, digoxin always presents a large positive benefit in morbidity reduction, which is one of the big deals for the future. The risk for major adverse effects such as increase in mortality should be dramatically reduced by lowering the daily dose for maintaining serum concentrations lower than 1 ng/mL. In terms of AF, digoxin remains one of three drugs used for rate control in AF. Even if digoxin alone is insufficient in providing rate control during exertion in most patients, the optimal cardiac rate both at rest and at exertion is, however, still undetermined, as is the importance of achieving sufficient rate control in asymptomatic patients. Nevertheless, because of its low cost and accumulated knowledge and expertise in prescription during the last decades, digoxin probably would remain an undisputed medication for rate control AF, especially for heart failure patients.

Furthermore, it now appears that cardiac glycosides are involved in complex cell signal transduction mechanisms that may have important consequences in their application to the prevention and/or treatment of malignant diseases. Population with AF or heart failure are elderly and often concerned about cancer. The potential role of digoxin in this manner might be seen as a supplementary reason to be prescribed in the future.

Disclosure

The authors report no conflicts of interest in this work.

References


